Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: Results from the long-term intervention with pravastatin in ischemic disease study

Journal of the American Heart Association

Volumn 2, Issue 5, 2013, Pages 1-13

  White, Harvey D ^a   Simes, John ^b   Stewart, Ralph A H ^a   Blankenberg, Stefan ^c   Barnes, Elizabeth H ^b   Marschner, Ian C ^b,k   Thompson, Peter ^d   West, Malcolm ^e   Zeller, Tanja ^c   Colquhoun, David M ^f   Nestel, Paul ^g   Keech, Anthony C ^b   Sullivan, David R ^h   Hunt, David ⁱ   Tonkin, Andrew ^j  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f GREENSLOPES PRIVATE HOSPITAL   (Australia)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j MONASH UNIVERSITY   (Australia)

^k MACQUARIE UNIVERSITY   (Australia)

more..

Author keywords

Biomarkers; Lipid; Lp PLA2; Pravastatin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; PLACEBO; PRAVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOLECULAR DYNAMICS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ADULT; BLOOD; CORONARY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; TIME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84891705653     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000360     Document Type: Article

References (23)

1. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoproteinassociated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338(Pt 2):479-487.
2. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523-2529.
3. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-C18.
4. The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536-1544.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
6. Heart Protection Study Collaborative Group. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med. 2010;268:348-358.
7. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006;113:1745-1752.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
9. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162-1169.
10. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A LIPID Study Investigators. Long-term risk stratification for survivors of acute coronary syndromes: results from the long-term intervention with pravastatin in ischemic disease (LIPID) study. J Am Coll Cardiol. 2001;38:56-63.
11. Packard CJ, O'Reilly DSJ, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GDO West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
12. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923-931.
13. Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26:106-111.
14. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115:2715-2721.
15. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005;182: 193-198.
16. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W. Relationship of lipoproteinassociated phospholipase A(2) mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem. 2012;58:877-886.
17. Song JX, Ren JY, Chen H. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-Rhoa-p38 mitogen-activated protein kinase pathway. J Cardiovasc Pharmacol. 2011;57:213-222.
18. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302-1309.
19. Wilensky RL, Shi Y, Mohler ER III, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066.
20. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoproteinassociated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-1182.
21. White HD, Held C, Stewart RA, Watson D, Harrington R, Budaj A, Steg G, Cannon C, Tarka E, Krug-Gourley S, Wittes J, Trivedi T, Wallentin L STABILITY Steering Committee. Study design and rationale for the clinical outcomes of the STABILITY Trial (stabilisation of atherosclerotic plaque by initiation of darapladib therapy) comparing darapladib versus placebo in patients with clinical coronary heart disease). Am Heart J. 2010;160:655-661.
22. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, Maggioni AP, Bode C, Weaver D, Johnson JL, Cicconetti G, Lukas MA, Tarka E, Cannon CP. Study design and rationale for the stabilization of plaques using darapladib-thrombolysis in myocardial infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011;162:613-619.
23. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints. New York: Springer; 2005.